The Australasian Gastro-Intestinal Trials Group (AGITG) Consumer Advisory Panel (CAP) recently made a submission to the funding for rare cancers Senate Inquiry.
On 29 November 2016 the Senate established a select committee known as the Select Committee into Funding for Research into Cancers with Low Survival Rates to inquire and report on the impact of health research funding models on the availability of funding for research into cancers with low survival rates.
The closing date for submissions was 31 March 2017. The committee is to inquire and report by 28 November 2017.
The AGITG Consumer Advisory Panel made a submission to the inquiry with the following recommendations:
1. Define “low survival cancers”.
2. Annual Commonwealth funding targets could be set: e.g. for 30% of cancer funds to be allocated to funding studies into low survival rate cancers, provided the high quality criteria of the funding program is maintained.
3. Establish transparent, routine reporting of the incidence and mortality of rare cancers as a subset of low survival rate cancers, as well as transparent, routine reporting of funding allocations to low survival cancers. Monitoring and regular reporting is needed to know if we are achieving any change (and return on investment of any new funding models)
4. Under the Australian Medical Research and Innovation Strategy provision should be made for the 2019 ‐ 2021 Priorities to specifically address international (and local) collaborative research into low survival rate cancers.
5. A sustained focus on ‘low survival cancers’ will be required to achieve enduring change to these rare or ‘difficult to treat’ cancers. Cancer Australia should be tasked with developing, implementing and maintaining a National Cancer Research Plan which among other research matters provides specific reference for implementing strategies to address “low survival and difficult to treat” cancers
For a copy of the complete submission click here